Clinical trialNCT07408089TerminatedPhase 1Interventional

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

SponsorBoundless Bio, Inc.Enrollment8Advanced Breast CancerBreast CancerMetastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert C. Doebele, MD, PhD
Boundless Bio, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

the Start Center for Cancer Research
Los Angeles, California, United States
the Start Center for Cancer Research
Lake Success, New York, United States
Next Oncology
Austin, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Next Oncology
Houston, Texas, United States
Next Oncology
San Antonio, Texas, United States
the Start Center for Cancer Care
San Antonio, Texas, United States
Next Oncology
Fairfax, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

BBI-940Fulvestrant →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Feb 2026
Primary completion: 28 Jul 2026
Completion: 28 Jul 2026
Last update posted: 19 Aug 2026
Registered enrollment: 8
Registry id: NCT07408089

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.